CSL - CSL
CSL Limited (ASX: CSL) is an Australian biopharmaceutical company. Its business is manufacturing medical products, including things such as blood plasma derivatives, antivenins and vaccines. CSL was first listed on the Australian Stock Exchange in 1994.
CSL began life in 1916 as the Commonwealth Serum Laboratories, a government body created primarily to manufacture vaccines. It occupied a building at Melbourne Hospital before moving to purpose-built premises elsewhere in Melbourne in 1919. From 1928 Commonwealth Serum Laboratories became involved in research and manufacture of antivenins. It was privatized and its name shortened to CSL Limited in 1994.
In 2004 CSL acquired the German medical company Aventis Behring.
Today CSL has three divisions. CSL Behring manufacturing, markets and develops plasma products, Intellectual Property Licensing licenses CSL’s intellectual property to third parties, and Other Human Health, which comprises CSL Bioplasma and CSL Biotherapies and manufactures biotherapeutic products.
CSL’s profits in 2008 were AUD$3.8 billion. CSL recorded a large jump in profits in the six months to 31 December 2009 as a result of sales of their swine flu vaccine.
Headquarters are in Melbourne, Australia. CSL also has headquarters in Pennsylvania, United States, and manufacturing operations in Switzerland, Germany and the United States.
Stock Symbol / Ticker: